Vacunacion Profesionales

Morbidity and Mortality Weekly Report
Recommendations and Reports / Vol. 60 / No. 7 November 25, 2011

Immunization of Health-Care Personnel
Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html.

U.S. Department of Health and Human Services Centers for Disease Control andPrevention

Recommendations and Reports

CONTENTS
Introduction ............................................................................................................2 Methods....................................................................................................................2 Diseases for Which Vaccination Is Recommended ....................................3 Diseases for WhichVaccination Might Be Indicated in Certain Circumstances ................................................................................................... 25 Other Vaccines Recommended for Adults ................................................ 28 Acknowledgments ............................................................................................. 29References............................................................................................................. 29

Disclosure of Relationship

CDC, our planners, and our content experts wish to disclose that they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. This report will not include any discussion of theunlabeled use of a product or a product under investigational use with the exception of the following situations: 1. For varicella postexposure prophylaxis for persons without evidence of immunity who have contraindications for vaccination and who are at risk for severe disease and complications, the product currently used in the United States, VariZIG (Cangene Corporation, Winnipeg, Canada), isavailable under an Investigational New Drug Application Expanded Access Protocol. 2. The interval between administration of Td and Tdap might be 37.7°C) (1%–6%) (64–67). However, in placebo-controlled studies, these side effects were reported no more frequently among persons receiving hepatitis B vaccine than among persons receiving placebo (40,41,64–67). Revaccination is not associated with an increasein adverse events. Hepatitis B vaccination is contraindicated for persons with a history of hypersensitivity to yeast or any vaccine component (4,64–66). Persons with a history of serious adverse events (e.g., anaphylaxis) after receipt of hepatitis B vaccine should not receive additional doses. As with other vaccines, vaccination of persons with moderate or severe acute illness, with or withoutfever, should be deferred until illness resolves (4). Vaccination is not contraindicated in persons with a history of multiple sclerosis, Guillain-Barré Syndrome, autoimmune disease (e.g., systemic lupus erythematosis and rheumatoid arthritis), or other chronic diseases. Pregnancy is not a contraindication to vaccination; limited data suggest that developing fetuses are not at risk for adverseevents when hepatitis B vaccine is administered to pregnant women (4,68). Available vaccines contain noninfectious hepatitis B surface antigen (HBsAg) and do not pose any risk for infection to the fetus.

MMWR / November 25, 2011 / Vol. 60 / No. 7

5

Recommendations and Reports

Recommendations
Two single-antigen hepatitis B vaccines, Recombivax HB (Merck & Co., Inc., Whitehouse Station,New Jersey) and Engerix-B (GlaxoSmithKline Biologicals, Rixensart, Belgium) and one combination hepatitis A and hepatitis B vaccine, Twinrix (GlaxoSmithKline Biologicals), are available in the United States. Primary vaccination consists of ≥3 intramuscular doses of hepatitis B vaccine or of the combined hepatitis A and hepatitis B vaccine. The hepatitis vaccine series does not need to be...